1052 Tracking Resistance to Artemisinin Collaboration (TRAC)


Locations: Bangladesh (BD), Congo (Democratic Republic of the Congo) (CD), Cambodia (KH), Laos (LA), Myanmar (MM), Nigeria (NG), Thailand (TH), Vietnam (VN)

Partner study description

TRAC is investigating the scope and spread of parasite resistance to artemisinin-based therapies at sites across Asia and Africa. The first TRAC study has been completed. This multi-centre, open-label randomised trial studied the clearance rates of peripheral blood P. falciparum parasitaemias in patients with acute uncomplicated falciparum malaria treated with two different doses of artesunate. Findings were used to validate the recently discovered kelch13 marker of artemisinin resistance. Working with MalariaGEN, TRAC samples have been sequenced and analysed for features of population genetics and signatures of selection, and contributed to the genetic basis of a genome-wide associations study for genetic markers of artemisinin resistance. Where samples were found to contain P. vivax data, for example due to mixed infection, this data was contributed to the P. vivax Genome Variation project.

Key People

Prof Nicholas J White
Professor of Tropical Medicine and Chair of Wellcome Trust SE Asian Tropical Medicine Research Programmes
Mahidol-Oxford Tropical Medicine Research Unit (MORU), Thailand
Centre for Tropical Medicine and Global Health, University of Oxford, UK
Professor Elizabeth Ashley
Lao-Oxford-Mahosot Hospital- Wellcome Trust Research Unit, Mahosot Hospital, Quai Fa Ngum, Vientiane, Lao PDR
Centre for Tropical Medicine and Global Health, University of Oxford, UK